|Slideshows|February 21, 2018

3 New Things About ADHD

Who’s filling ADHD prescriptions now?

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Starting ADHD Treatment in Adolescents, With Ann Childress, MD

ByGustavo Alva, MD, DFAPA,Ann Childress, MD

June 26th 2026

New Phase 3 Post Hoc Analyses of Centanafadine for the Treatment of Adults With ADHD

ByLenard A. Adler, MD

June 26th 2026

AI-Driven Biomarker Discovery from Wearables in Neuropsychiatric Research

ByMark Gerstein, PhD

June 5th 2026

FDA Issues CRL for CTx-1301 for Treatment of ADHD

ByJessica Walters

June 2nd 2026

Balancing Efficacy and Risk in ADHD Pharmacotherapy

ByHelene Alphonso, DO

June 1st 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

3 New Things About ADHD

Related Content

Starting ADHD Treatment in Adolescents, With Ann Childress, MD

New Phase 3 Post Hoc Analyses of Centanafadine for the Treatment of Adults With ADHD

AI-Driven Biomarker Discovery from Wearables in Neuropsychiatric Research

FDA Issues CRL for CTx-1301 for Treatment of ADHD

Balancing Efficacy and Risk in ADHD Pharmacotherapy

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Starting ADHD Treatment in Adolescents, With Ann Childress, MD

The Psychiatric Pipeline in Review: Quarter 2, 2026

New Positive Data From Largest Real-World Study of Deep TMS in Patients With Comorbid PTSD and MDD

June 2026 in Review: Updates on the Psychiatric Treatment Pipeline

Tribalism in Psychiatry: On the Mind of John J. Miller, MD